| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | WVE-006 Alpha-1 antitrypsin deficiency (AATD) — clinical development plan and regulatory pathway (company guidance item) | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Respiratory System | |
NDA Submission example | WVE-006 Alpha-1 antitrypsin deficiency (AATD) — clinical development plan and regulatory pathway (company guidance item) | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Respiratory System | |
NDA Submission example | WVE-006 Alpha-1 antitrypsin deficiency (AATD) — clinical development plan and regulatory pathway (company guidance item) | NDA | — | Subscribe to access the data. | RNA-Based Therapies | Respiratory System |
Recent Updates
Recently added Catalysts
Wave Life Sciences Ltd.$6.25
-0.21 (-3.41%)
C 47Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.23 B
EPS
-1.05
P/E Ratio
-
Value Trade
16.79 M
SEC Financials
Q1 2026Dilution Risk
Revenue
38.25 M
R&D Expenses
47.44 M
Operating CF
-59.55 M
Total Assets
583.54 M
Total Liabilities
71.81 M
Equity
511.73 M
D/E Ratio
12,345
-6.04 %
Week
-14.36 %
1 Month
-51.19 %
3 Month
-5.2 %
6 Month
-4.49 %
5 Year
-62.58 %
All Time
Cash Data
Cash Position
544.59 M
Monthly Burn
19.85 M
Runway
25.2 mo
Burn Trend
SEC Filing
Apr 28, 2026
Overview
Volume
3.55 M
52 Week Range
5.02 - 21.73
% held by Insiders
17.65 %
% held by Institutions
78.86 %
Enterprise Value
698.65 M
Total Shares
167.25 M
Short %
18.19 %
Float Shares
114.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Wave Life Sciences Ltd.
641Total events
6Upcoming
147Tier-1 (high impact)
2016 – 2028Coverage
Upcoming catalysts 6
Jul 14, 2026
T2Other Regulator Milestone
Singapore Court hearing to approve Scheme of Arrangement for redomiciliation
Event history 635
Q3 2026
◆Trial InitiationWVE-007Trial
Initiation of additional Phase 2 trials evaluating WVE-007 in combination with incretins and as post-incretin maintenance
obesitysource ↗
Jun 24, 2026
▲Trial InitiationWVE-007Trial
Initiation of Phase 2a portion of INLIGHT trial of WVE-007
obesity and cardiometabolic diseasessource ↗
Jun 24, 2026
▲Topline ReadoutWVE-007Clinical Data
Phase 1 single dose portion data at six months follow-up
obesitysource ↗
Jun 2026
◆FDA Feedback ReceivedWVE-006FDA Meeting
Regulatory feedback on potential accelerated approval pathway for WVE-006 anticipated mid-2026
AATD (Alpha-1 antitrypsin deficiency)source ↗
Jun 2026
◆Accelerated Approval PathwayWVE-006Designation
Wave plans to engage FDA on potential accelerated approval pathway for WVE-006
alpha-1 antitrypsin deficiencysource ↗
May 29, 2026
May 29, 2026
◆Poster PresentationWVE-008Presentation
Poster presentation at EASL Congress on preclinical data for WVE-008
PNPLA3 I148M liver diseasesource ↗
May 20, 2026
◆Oral PresentationPresentation
CEO Paul Bolno to participate in fireside chat at 2026 RBC Capital Markets Global Healthcare Conference
May 18, 2026
◆Oral PresentationWVE-006Presentation
Late-breaking oral presentation of data from RestorAATion-2 trial at ATS 2026
alpha-1 antitrypsin deficiencysource ↗
May 18, 2026
▲Topline ReadoutWVE-006Clinical Data
Updated data from RestorAATion-2 trial announced
alpha-1 antitrypsin deficiencysource ↗
Apr 29, 2026
◆Management ChangeCorporate
Singapore High Court hearing on application to convene shareholder meeting for redomiciliation
Drug Pipeline Intelligence
C47
Pipeline Score $252M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 69%
Micro Cap (rank 283 of 911)
Percentile RankWave Life Sciences Ltd. carries a moderate pipeline score (47/100), with $629M risk-adjusted pipeline value, led by WVE-007 in Overweight and Obesity (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WVE-007 Small molecule | Overweight and Obesity | Phase 1 | NCT06842186 | 14% | $343M | RECRUITING | 296 | VERY_FAST | C (59) | Dec 1, 2027 | MODERATE_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
WVE-007 | Obesity and Cardiometabolic Diseases | Phase 1 | 2026-06-24 | visceral fat reduction: -14%; total fat reduction: -5%; waist circumference reduction: -3% Read More | Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases Read More | |
WVE-007 | Obesity and Cardiometabolic Diseases | Phase 1 | 2026-06-24 | visceral fat reduction: -14%; total fat reduction: -5%; waist circumference reduction: -3% Read More | Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases Read More | |
WVE-007 | Obesity and Cardiometabolic Diseases | Phase 1 | 2026-06-24 | visceral fat reduction: -14%; total fat reduction: -5%; waist circumference reduction: -3% Read More | Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WVE
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
WVE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
WVE▼ -3.4%today
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Wave Life Sciences Ltd. has received shareholder approval for its proposed redomiciliation to the United States. The Singapore Court is set to hear the application for the Scheme of Arrangement on July 14, 2026. This move aims to enhance the company's operational capabilities and align its corporate structure with its business strategy in RNA medicines.
Read more →WVEWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
Wave Life Sciences has initiated the Phase 2a portion of the INLIGHT trial for WVE-007, targeting obesity and related cardiometabolic conditions. The trial will assess multiple outcomes, including body composition and metabolic health in individuals with higher BMI. Early Phase 1 results indicate significant reductions in visceral fat with a favorable safety profile, supporting further development of WVE-007.
Read more →WVEWave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences to Present at Upcoming Investor Conferences
Read more →WVEWave Life Sciences Ltd. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
Johnson Fistel is investigating Wave Life Sciences Ltd. for potential violations of federal securities laws in light of investor losses. This comes after a significant decline in Wave's stock following positive interim Phase 1 data from its WVE-007 clinical trial. The firm aims to determine if stakeholders can recover their losses as a result. Investors who have suffered losses are encouraged to contact Johnson Fistel for more information.
Read more →WVEWave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
Read more →WVE▼ -5.5%on this newsshared move
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing Data reinforce WVE-006's potential to address both lun
Wave Life Sciences announced positive results from the RestorAATion-2 trial for WVE-006, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency. The trial showed significant reductions in harmful Z-AAT proteins and substantial increases in protective M-AAT levels. Safety data indicated no liver toxicities and a favorable response to infrequent subcutaneous dosing. Wave Life Sciences is on track to seek FDA feedback for accelerated approval in mid-2026.
Read more →WVEWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences Ltd. announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference in New York City on May 20, 2026. The event will be accessible via a live webcast, with a replay available afterward. Wave Life Sciences focuses on RNA medicines and has a diverse pipeline addressing various diseases.
Read more →WVE▲ +8.4%on this news
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
Wave Life Sciences reported its Q1 2026 financial results, highlighting progress in its clinical trials, particularly for WVE-007 and WVE-006. The FDA has accepted the Phase 2a trial for WVE-007, which targets obesity, while data from the RestorAATion-2 trial for WVE-006 will be presented at an upcoming conference. The company remains well-capitalized with substantial cash reserves.
Read more →WVEWave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
Wave Life Sciences Ltd. will host a live webcast and conference call on April 28, 2026, to discuss its first quarter 2026 financial results and provide business updates. The event will be accessible via the company's investor relations website. Wave is known for its RNA medicines platform and has a diverse pipeline targeting several diseases.
Read more →WVEWave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
Wave Life Sciences is seeking approval for a redomiciliation from Singapore to the U.S. The Singapore High Court will hear the application on April 29, 2026. This move aims to enhance operational capabilities and shareholder value, but it remains subject to shareholder and court approval.
Read more →WVEWave Life Sciences Announces Proposed Redomiciliation to the United States
Wave Life Sciences has announced a plan to redomicile its parent company from Singapore to the United States, aiming to enhance operational efficiency and shareholder value. The move is expected to streamline regulatory compliance and reduce costs, aligning the company's domicile with its existing U.S. operations. The redomiciliation is subject to shareholder and court approvals, with expectations for completion in mid-2026.
Read more →WVE▼ -49.6%on this news
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
Wave Life Sciences announced positive interim results from the Phase 1 INLIGHT trial of WVE-007, demonstrating significant reductions in visceral fat and waist circumference after six months. The trial showed that a single 240 mg dose led to improvements in body composition, with muscle preservation. The upcoming Phase 2a trial aims to evaluate further efficacy in individuals with higher BMI and comorbidities.
Read more →WVE▼ -49.6%on this newsshared move
WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims for investors of Wave Life Sciences Ltd. after the company disclosed interim Phase 1 clinical data for WVE-007. The data revealed only modest reductions in body weight, which led to a significant stock price decline on March 26, 2026. The firm is examining whether the company's executive officers complied with federal securities laws amidst these losses for investors. Individuals who purchased securities in Wave Life Sciences and suffered losses are encouraged to join the investigation.
Read more →WVEWave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
Wave Life Sciences announced the acceptance of a late-breaking oral presentation for WVE-006 at the ATS International Conference. The presentation will include new data from both the 400 mg multidose and 600 mg single-dose cohorts of the RestorAATion-2 clinical trial. The conference is set to take place from May 15-20, 2026, in Orlando, Florida.
Read more →WVE▲ +5.6%on this news
Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Wave Life Sciences reported its fourth quarter and full year 2025 financial results, highlighting significant advancements in its clinical pipeline. The company is on track for a data update on WVE-007 in early 2026, which has shown promising fat loss results. Additionally, Wave is advancing its RNA editing portfolio with WVE-006 and WVE-008, aiming for potential accelerated approvals. The company remains well-capitalized with a cash runway extending into 2028.
Read more →WVEWave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Wave Life Sciences Ltd. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Paul Bolno will participate in an analyst-led fireside chat. The event will be accessible via a live webcast, with a replay available afterward. Wave focuses on RNA medicines to address various health conditions.
Read more →WVEWave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Wave Life Sciences Ltd. will conduct a live webcast and conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results, along with business updates. The event emphasizes the company's focus on RNA medicines to transform human health. Analysts can participate in the Q&A section during the call, and a recorded version will be available afterward. The company is committed to advancing its diverse pipeline, including programs for obesity, alpha-1 antitrypsin deficiency, and liver disease.
Read more →WVEWave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has announced plans to accelerate regulatory engagement for WVE-006, a novel RNA editing therapy for alpha-1 antitrypsin deficiency (AATD). The company has regained full rights to the therapy from GSK and aims to engage the FDA for potential accelerated approval by mid-2026. Clinical trial data is expected in 2026, supporting the therapy's promising profile.
Read more →WVEWave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave Life Sciences presented its strategic goals for 2026 at the J.P. Morgan Healthcare Conference, outlining plans for the development of WVE-007 targeting obesity and advancing its RNA editing portfolio. The company aims to initiate the Phase 2a trial for WVE-007 in the first half of 2026 after early data showed favorable results. Furthermore, Wave expects to file a Clinical Trial Application for WVE-008, addressing a significant liver disease, in the same year. The company remains well-funded, with expectations for cash coverage until 2028, facilitating the advancement of its clinical programs.
Read more →WVE▼ -6%on this news
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Wave Life Sciences Ltd. announced that CEO Paul Bolno will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The event will take place in San Francisco, CA, and a live webcast will be available for interested parties. Wave Life Sciences is known for its RNA medicines platform and has a diversified pipeline targeting various diseases.
Read more →WVEWave Life Sciences Highlights Strategic Priorities for 2026 at the 44 th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Wave Life Sciences has outlined its strategic priorities for 2026, focusing on the advancement of WVE-007 for obesity and the RNA editing portfolio. The company plans to initiate a Phase 2a trial for WVE-007 and expects to file a Clinical Trial Application for WVE-008 targeting liver disease. Preliminary data shows WVE-007 has favorable body composition effects and a potential for novel dosing regimens. The company maintains a strong cash position to support its initiatives through 2028.
Read more →WVE▼ -5.1%on this news· ran to -24% by day 3
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences Ltd. has announced the pricing of its upsized public offering, which includes 15,789,475 ordinary shares priced at $19.00 each and pre-funded warrants for additional shares. The offering is expected to generate approximately $350 million in gross proceeds and is set to close around December 11, 2025, pending customary conditions. The company aims to utilize the funds to advance its RNA medicines platform and pipeline.
Read more →WVE▲ +15.1%on this newsshared move
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences has announced a proposed public offering of $250 million in ordinary shares and pre-funded warrants. The offering is managed by Jefferies, Leerink Partners, and BofA Securities, with a 30-day option for underwriters to purchase additional shares. The final terms will be disclosed in a prospectus supplement filed with the SEC.
Read more →WVE▲ +147.3%on this news· ran to +185% by day 1shared move
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
Wave Life Sciences announced positive interim data from its Phase 1 INLIGHT trial for WVE-007, an investigational treatment for obesity. A single 240 mg dose resulted in significant reductions in visceral and total body fat, alongside an increase in lean mass after three months. The treatment was well tolerated, with plans for Phase 2 trials underway to explore its use as both a monotherapy and in combination with other therapies.
Read more →WVE▲ +147.3%on this news· ran to +185% by day 1shared move
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
Wave Life Sciences is set to announce interim data from its Phase 1 INLIGHT trial for WVE-007, an investigational treatment for obesity, on December 8, 2025. The trial evaluates the safety and efficacy of WVE-007, which targets INHBE mRNA. The announcement will be followed by an investor conference call and webcast.
Read more →WVEWave Life Sciences Corporate Presentation
Wave Life Sciences showcased its advances in RNA medicine during a corporate presentation. The company is pursuing innovative therapies using its proprietary PRISM platform, with a focus on multiple conditions including obesity and genetic disorders. Their pipeline includes promising candidates such as WVE-007 for obesity and WVE-006 for Alpha-1 antitrypsin deficiency, which is partnered with GSK. However, the presentation highlighted the uncertainties and risks associated with their forward-looking statements, typical for biopharma firms operating in a dynamic industry.
Read more →WVE▼ -10.3%on this news
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Wave Life Sciences reported positive clinical results for its obesity treatment WVE-007 and AATD therapy WVE-006 in the third quarter of 2025. The INLIGHT trial demonstrated significant reductions in Activin E, supporting the drug's potential for effective fat loss while preserving muscle mass. The company also highlighted a strong financial position with substantial cash reserves, enabling continued development of its RNA medicines pipeline.
Read more →WVEWave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
Wave Life Sciences is set to present preclinical data for WVE-007, a GalNAc-siRNA therapeutic aimed at obesity, at ObesityWeek 2025. The data indicates that WVE-007 can promote fat loss while preserving muscle mass, with significant improvements in metabolic health. The ongoing INLIGHT clinical study has shown promising target engagement and safety, suggesting a potential for infrequent dosing.
Read more →WVEWave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
Wave Life Sciences Ltd. (Nasdaq: WVE) will host a live webcast and conference call on November 10, 2025, to review its third quarter 2025 financial results and provide business updates. The event will allow analysts and investors to participate in a Q&A session. Wave Life Sciences focuses on RNA medicines and has a diversified pipeline addressing various disorders, highlighting its commitment to transforming human health.
Read more →WVECorrecting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Wave Life Sciences announced positive target engagement data from the INLIGHT clinical trial for WVE-007, a GalNAc-siRNA treatment for obesity. The trial demonstrated significant reductions in Activin E levels, indicating potential effectiveness. The treatment was well tolerated, and further updates on body composition and weight are expected in late 2025. Additionally, the company is advancing its RNA editing candidates, including WVE-008 for liver disease.
Read more →WVE▲ +8.8%on this newsshared move
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day Dose-dependent mean reductions of Activin E of up to 85% one month post single do
Wave Life Sciences has reported positive data from its INLIGHT clinical trial for WVE-007, demonstrating significant reductions in Activin E levels, which are expected to translate to effective obesity treatment. The results indicate dose-dependent mean reductions of Activin E of up to 85%, and the treatment is well tolerated, suggesting potential long-term dosing regimens. The company is set to provide multiple updates on the trial and additional data related to body composition and weight in the coming years, further affirming its innovative position in the RNA medicine field.
Read more →WVEWave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
Wave Life Sciences Ltd. announced a virtual Research Day scheduled for October 29, 2025, at 10:00 a.m. ET. The company will also participate in several investor conferences, including the Bernstein Healthcare Forum and Stifel Virtual Cardiometabolic Forum. These events will feature discussions on RNA editing therapeutics and other advancements in their pipeline.
Read more →WVE▼ -16.8%on this news
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences announced positive results from the ongoing RestorAATion-2 trial of WVE-006, showing durable production of serum AAT protein in patients with alpha-1 antitrypsin deficiency (AATD). The trial demonstrated the potential for WVE-006 to restore physiological AAT production, with favorable safety and tolerability. Data supports the feasibility of less frequent dosing, with further results expected in 2026.
Read more →WVEWave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manife
Wave Life Sciences reported positive financial results for Q2 2025 and provided significant updates on its clinical trials. The company's lead candidate, WVE-006, is advancing in the RestorAATion-2 study for AAT deficiency, with data expected in Q3 and Q4 2025. Additionally, WVE-007 showed promising results in the INLIGHT trial with expanded dosing. Wave holds a solid financial position, with $208.5 million cash on hand, ensuring a runway into 2027.
Read more →WVE▲ +7.9%on this news
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
Wave Life Sciences is set to host a live webcast on July 30, 2025, to discuss its second quarter financial results and provide business updates. The company focuses on RNA medicines and has a diversified pipeline addressing various disorders, including Duchenne muscular dystrophy and Huntington's disease. The event will be accessible via their investor relations website.
Read more →WVEWave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Wave Life Sciences announced promising preclinical data for its obesity treatment candidate WVE-007 at the ADA's Annual Scientific Sessions. The GalNAc-siRNA is designed to silence INHBE mRNA, leading to fat loss while preserving muscle mass, as well as reducing inflammation in adipose tissue. The findings suggest a potential therapeutic approach that could transform obesity treatment, offering healthy weight reduction and reduced risks for conditions such as type 2 diabetes. WVE-007 is currently being evaluated in ongoing clinical trials, with initial data expected later this year.
Read more →WVEWave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference
Read more →WVEWave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
Wave Life Sciences has appointed Dr. Christopher Wright as Chief Medical Officer. Dr. Wright brings extensive experience in global development and regulatory functions, aimed at advancing Wave's RNA medicines. He previously held key positions at various biotechnology companies, enhancing his qualifications for this role. His appointment is seen as crucial for Wave as it seeks to expand and improve its clinical pipeline of RNA-based therapies.
Read more →WVEWave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weigh
Wave Life Sciences has reported its financial results for Q1 2025, highlighting significant progress in various clinical trials. Dosing is complete for the first two cohorts of the INLIGHT trial investigating the obesity drug WVE-007, with clinical data expected in 2H 2025. The company also reports positive outcomes from the FORWARD-53 trial in Duchenne muscular dystrophy (DMD) and anticipates further advancements in its pipeline. Additionally, Wave has solid financial backing with $243.1 million to support ongoing and future projects.
Read more →WVEWave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025
Wave Life Sciences Ltd. will host a live webcast and conference call on May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 financial results and offer business updates. Participants can access the event through the company's investor relations website, with recordings available post-event. Wave Life Sciences focuses on RNA medicines, aiming to address both rare and common disorders.
Read more →WVE▲ +6.1%on this news
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531 Statistically significant and
Wave Life Sciences has announced positive data from the Phase 2 FORWARD-53 clinical trial of WVE-N531, an exon skipping therapy for boys with Duchenne muscular dystrophy. The trial showed significant functional benefits, including a 3.8-second improvement in Time-to-Rise and a notable reduction in muscle damage and inflammation after 48 weeks of treatment. WVE-N531 proved to be safe and well-tolerated, leading Wave to plan a New Drug Application submission in 2026. This data highlights the therapy's potential to transform treatment for patients amenable to exon 53 skipping.
Read more →WVE▲ +11.7%on this news
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment comple
Wave Life Sciences reported their fourth quarter and full year financial results for 2024, highlighting significant progress in their clinical trials. Dosing has commenced in the INLIGHT trial for WVE-007, aimed at addressing obesity, with clinical results anticipated in the second half of 2025. The company also continues to advance multiple trials for genetic disorders, including the RestorAATion-2 clinical study and a Phase 2/3 study for Huntington's disease. They maintain a robust cash position, allowing for ongoing development efforts into 2027.
Read more →WVEWave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
Wave Life Sciences Ltd. is set to host a webcast and conference call on March 4, 2025, to discuss its fourth quarter and full year 2024 financial results. As a clinical-stage biotechnology company, Wave focuses on RNA medicines that aim to address both rare and common disorders. The event indicates potential updates on their diverse pipeline, which includes treatments for conditions such as Alpha-1 antitrypsin deficiency and Huntington's disease. Archived access to the webcast will be available following the live event for interested stakeholders.
Read more →WVEWave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
Wave Life Sciences has initiated the Phase 1 INLIGHT clinical trial for WVE-007, a long-acting GalNAc-siRNA targeting obesity. The trial is designed to assess safety, tolerability, and other metrics in adults with overweight or obesity. Proof-of-concept data is anticipated in 2025, and WVE-007 represents a novel therapeutic approach by targeting the INHBE mRNA for health outcomes related to weight loss. The therapy is positioned to potentially benefit over a billion individuals suffering from obesity worldwide.
Read more →WVEWave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
Read more →WVEWave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
Read more →WVEWave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
Wave Life Sciences Ltd. has announced that its President and CEO, Paul Bolno, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2025. The presentation will highlight the company's advancements in RNA medicine, a key focus of their research and development efforts. Attendees will have the opportunity to access a live webcast and a replay of the presentation afterwards. Wave Life Sciences aims to transform human health through its diverse pipeline of RNA-targeting therapies.
Read more →WVE▼ -8.9%on this newsshared move
Wave Life Sciences to Present at Jefferies London Healthcare Conference
Wave Life Sciences Ltd. is set to present at the Jefferies London Healthcare Conference on November 20, 2024. CEO Paul Bolno will participate in an analyst-led fireside chat during the event. The presentation can be accessed via the company's Investor Relations webpage, and a replay will be available afterward. Wave Life Sciences focuses on RNA medicines and has a diversified pipeline targeting various health conditions including Duchenne muscular dystrophy and Huntington's disease.
Read more →WVEWave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency a
Wave Life Sciences reported strong third quarter results for 2024, highlighting its first-ever RNA editing in humans achieved through the RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency. The company is advancing its wholly owned pipeline, including key milestones for clinical trials aimed at obesity and Duchenne muscular dystrophy. Furthermore, FDA discussions regarding accelerated approval for WVE-003 are underway, reflecting a positive regulatory outlook. With a solid cash position extending into 2027, Wave Life Sciences is well-positioned for future advancements in RNA medicines.
Read more →WVEWave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
Wave Life Sciences Ltd. will host a live webcast on November 12, 2024, to review its third quarter financial results and discuss business updates. The company is a clinical-stage biotechnology firm focused on RNA medicines, with a diversified pipeline that includes programs for Duchenne muscular dystrophy and other conditions. The event aims to provide insights into the company's progress and financial standing.
Read more →WVEWave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in
Wave Life Sciences announced significant developments during its Research Day, highlighting its growing pipeline, particularly the WVE-007 siRNA program targeting obesity, which is set to enter clinical trials in Q1 2025. The company also unveiled new RNA editing programs aimed at cardiometabolic diseases. The innovations in oligonucleotide chemistry and delivery mechanisms were emphasized, demonstrating the potential for Wave's RNA medicines to make a meaningful impact on treatment for multiple health conditions. The research showcases Wave's commitment to advancing solutions for unmet medical needs.
Read more →WVE▲ +74.1%on this news
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency Achieved proof-of-mechanism for Wave s RNA editing platform; restori
Wave Life Sciences has announced a significant milestone in RNA medicine with the first-ever therapeutic RNA editing in humans during its RestorAATion-2 trial for WVE-006, targeting alpha-1 antitrypsin deficiency (AATD). Initial results show that a single subcutaneous dose led to substantial increases in wild-type M-AAT protein levels, confirming the therapy's efficacy. The trial remains ongoing, with future data expected in 2025. Wave's advancements may provide new treatment options for AATD, especially considering the lack of approved therapies for AATD liver disease.
Read more →WVE▲ +74.1%on this news
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
Wave Life Sciences Ltd. has announced a virtual Research Day scheduled for October 30, 2024, to provide updates on its pipeline and innovative RNA programs. The event will showcase new advancements in RNA editing and siRNA programs while highlighting the progress of WVE-006 and the potential of WVE-007 as an obesity treatment. The company will feature insights from Dr. Mehmet Furkan Burak, an expert in obesity treatment, discussing the current landscape and unmet needs. Attendees will have access to live and archived webcasts of the event.
Read more →WVEWave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Wave Life Sciences has successfully closed its upsized public offering, raising gross proceeds of approximately $230 million. The underwriters fully exercised their option to purchase an additional 3,750,000 ordinary shares at the public offering price of $8.00 per share. This offering reflects strong market confidence in the company's biotechnology focus on RNA medicines, which target various health conditions. Wave's clinical pipeline includes programs for rare disorders, showcasing the company's commitment to transforming human health.
Read more →WVEWave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
Wave Life Sciences Ltd. will participate in the Chardan 8th Annual Genetic Medicines Conference, with the CEO presenting on October 1, 2024. The presentation will be available via a live webcast, with an archived replay accessible afterward. Wave's commitment to RNA medicines and its diverse pipeline addressing multiple diseases highlights its role in advancing healthcare.
Read more →WVE▲ +10%on this newsshared move
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences Ltd. priced a public offering of $200 million, comprising 23,125,001 ordinary shares and pre-funded warrants. This offering is set to close on September 27, 2024, pending customary closing conditions. The company has also granted underwriters a 30-day option for additional shares. Wave intends to use the proceeds to further its RNA medicines pipeline targeting various diseases.
Read more →WVE▲ +53.4%on this news· ran to +69% by day 1shared move
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping Mean muscle content-adjusted dystrophin expressi
Wave Life Sciences has announced positive interim data from its Phase 2 FORWARD-53 clinical trial of WVE-N531, an exon skipping oligonucleotide for boys with Duchenne muscular dystrophy (DMD). The interim analysis indicated significant dystrophin expression and an improvement in serum biomarkers related to muscle health. The treatment was found to be safe and well tolerated, supporting the potential for monthly dosing. Results from the complete trial are anticipated in the first quarter of 2025, along with possible feedback on accelerated approval from regulatory authorities.
Read more →WVE▲ +53.4%on this news· ran to +69% by day 1shared move
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Wave Life Sciences has announced a proposed public offering of $175 million, comprising ordinary shares and pre-funded warrants. The offering is underwritten, with J.P. Morgan and Leerink Partners leading the transaction. Although the company aims to fund its initiatives, there are risks associated with market conditions that may affect the offering's completion and terms. Detailed terms will be provided in a prospectus supplement to be filed with the SEC.
Read more →WVEWave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
Wave Life Sciences has received FDA's Rare Pediatric Disease Designation for WVE-N531, aimed at treating Duchenne muscular dystrophy (DMD). This designation underscores the significant needs in the DMD community and supports the company's innovative approach in drug development. Currently being evaluated in the FORWARD-53 trial, WVE-N531 has shown promising results in earlier studies, achieving high exon skipping levels significant for muscle function restoration. Results from the trial are expected in the third quarter of 2024, which could pave the way for additional treatments in the DMD pipeline.
Read more →WVEWave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update Successful clinical translation of Wave s RNA medicines platform in HD patients with WVE-003 provides further validation of Wa
Wave Life Sciences announced its financial results for Q2 2024 and highlighted advancements in its RNA medicines platform. The company reported successful data from the SELECT-HD trial with WVE-003, leading to discussions with regulators for an accelerated approval pathway. Upcoming trial data for WVE-N531 in DMD and WVE-006 in AATD is also anticipated, which could further validate its therapeutic pipeline. Additionally, preclinical data for the obesity treatment WVE-007 is expected this Fall.
Read more →WVE▼ -6.8%on this news
Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
Wave Life Sciences Ltd. will host a live webcast and conference call on August 8, 2024, at 8:30 a.m. ET to discuss its second quarter 2024 financial results and provide business updates. Participants can access the call through the company's investor events webpage. Wave Life Sciences is focused on advancing RNA medicines and has a diverse pipeline targeting various diseases.
Read more →WVE▼ -8.4%on this news
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington s Disease Statistically significant, potent, a
Wave Life Sciences has announced positive results from its Phase 1b/2a SELECT-HD clinical trial for WVE-003, targeting Huntington's disease. The trial showed a 46% mean reduction in mutant huntingtin protein in participants, along with preservation of healthy wild-type huntingtin levels. These results are statistically significant, correlating with a slowdown in caudate atrophy, and suggest a potential path for accelerated approval of the treatment. The company plans to engage with regulators to discuss the findings and ongoing development of its RNA medicines pipeline.
Read more →WVEWave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
Wave Life Sciences Ltd. announced upcoming presentations at two conferences, including the Obesity & Weight Loss Drug Development Summit and the RNA Editing Summit. The company will showcase its innovative siRNA program targeting obesity and the advancements in its RNA editing therapeutics, particularly WVE-006 for Alpha-1 antitrypsin deficiency. The INHBE program is designed to promote healthy weight management and metabolic profiles, while the RNA editing pipeline aims to correct mRNA and restore proteins. Wave Life Sciences anticipates sharing significant data on these programs in 2024.
Read more →WVEWave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
Wave Life Sciences Ltd. will present at the 2024 Jefferies Global Healthcare Conference in New York City on June 6, 2024. Paul Bolno, the President and CEO, will lead the presentation at 7:30 a.m. ET. The event emphasizes Wave's commitment to advancing RNA medicines through innovative platforms and a diverse pipeline tackling various health challenges. A live webcast will be available during the presentation, with a replay accessible afterward.
Read more →WVEWave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
Wave Life Sciences has announced the appointment of Dr. Erik Ingelsson as Chief Scientific Officer, who will lead the company's therapeutic portfolio strategy. His experience at GSK in target discovery and validation, along with extensive expertise in genetics and metabolic diseases, positions him to significantly impact Wave's RNA medicine initiatives, including the INHBE program aimed at obesity. This appointment arrives as the company anticipates multiple near-term clinical data readouts and aims to leverage Dr. Ingelsson's background to accelerate drug development. However, there are inherent risks surrounding future outcomes and clinical trial data delivery.
Read more →WVEWave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD rema
Wave Life Sciences has reported its financial results for Q1 2024 and provided updates on key developments. The company is progressing with the RestorAATion-2 clinical trial for WVE-006 in patients with AATD, with expected proof-of-mechanism data anticipated later this year. Additionally, the company is set to initiate its INHBE program clinical trial for obesity in Q1 2025, with promising preclinical results. Wave also highlighted continued collaboration with GSK and progress toward clinical data releases in its other programs.
Read more →WVEWave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that its CEO, Paul Bolno, will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The event will take place in New York City and will be accessible via a live webcast. Wave Life Sciences is known for its RNA medicines platform that aims to address a variety of disorders, further solidifying its position in the biotechnology sector.
Read more →WVEWave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
Wave Life Sciences Ltd. is scheduled to host a live webcast and conference call on May 9, 2024, to review its first quarter financial results and share business updates. The event will be accessible online through their investor website. Wave specializes in RNA medicines, with a diversified pipeline targeting diseases such as Duchenne muscular dystrophy and Huntington's disease. Interested analysts can register to participate in the call, and an archived version of the webcast will be available afterward.
Read more →WVEWave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Read more →WVEWave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing
Wave Life Sciences has announced significant progress in its collaboration with GSK, including the selection of two programs for advancement to development candidates, which utilize Wave's advanced GalNAc-siRNA technology. The company expects to begin clinical trials for its INHBE obesity program in the first quarter of 2025. Financially, Wave is positioned to receive up to $3.3 billion in milestone payments from GSK. The collaboration spans multiple RNA-targeting modalities with ongoing target validation in various therapy areas.
Read more →WVE▲ +31.3%on this news· ran to +42% by day 1
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update INHBE lead clinical candidate selected; potential best-in-class treatment for obesity with potent and durable si
Wave Life Sciences reported its financial results for Q4 and the full year 2023, highlighting significant progress across its clinical pipeline. The company has advanced its INHBE program for obesity treatment, expecting clinical trials to begin in Q1 2025, and emphasized financial stability with a cash balance of $200 million. Key upcoming events include data readouts for WVE-006 and results from other trials, contributing to Wave's confidence in their innovative approaches to RNA therapeutics. The CEO expressed optimism regarding the transformative potential of their pipeline.
Read more →WVEWave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
Wave Life Sciences Ltd. is set to host a live webcast and conference call on March 6, 2024, to discuss its fourth quarter and full year 2023 financial results. The event will allow analysts to participate in a Q&A session and will be accessible through the company’s investor website. Wave Life Sciences focuses on RNA medicines with a diversified pipeline addressing various disorders, indicating a commitment to advancing innovative treatments.
Read more →WVE▲ +10.9%on this newsshared move
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
Read more →WVE▲ +5.1%on this news
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Wave Life Sciences announced key upcoming milestones and recent achievements, including multiple data catalysts planned throughout 2024. The company is poised to provide the first-ever RNA editing proof-of-mechanism data from its WVE-006 program in Alpha-1 Antitrypsin Deficiency. Additionally, the INHBE program targeting obesity is ahead of schedule with clinical candidate selection expected in Q3 2024. Wave is also advancing its DMD and Huntington's Disease programs, with data expected to showcase progress in these areas in the coming year.
Read more →WVEWave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference
Wave Life Sciences Ltd. has announced that CEO Paul Bolno will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. The presentation will focus on the company's innovative RNA medicine development efforts. Additionally, a live webcast of the event will be available on the company's Investor Relations page for those unable to attend. Wave Life Sciences aims to tackle genetically defined diseases using its proprietary PRISM platform.
Read more →WVEForward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future
Wave Life Sciences announced forward-looking statements regarding its business, including details about its pipeline and collaborations, particularly with GSK. The company has achieved a $20 million milestone under this collaboration and secured funding to extend its operational runway. However, they emphasized the inherent risks and uncertainties associated with these predictions, which may impact future outcomes. Upcoming clinical trials for their RNA medicines targeting conditions like AATD, DMD, and HD are eagerly anticipated.
Read more →WVEWave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy
Wave Life Sciences has initiated dosing in the Phase 2 FORWARD-53 clinical trial for WVE-N531, targeting boys with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. The trial is designed to evaluate dystrophin protein levels after treatment, with data expected in 2024. Previous trials indicated high levels of exon skipping and safety, establishing a strong foundation for the current study. The successful outcome of FORWARD-53 may provide insights into addressing the unmet needs in DMD treatment.
Read more →WVE▼ -30.4%on this news
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
Wave Life Sciences Ltd. has announced the pricing of a public offering of 20 million ordinary shares at $5.00 per share, aiming to raise approximately $100 million. This offering is part of the company's strategy to bolster its clinical programs focusing on RNA medicines for serious diseases. The offering is contingent upon customary closing conditions and is expected to close on December 11, 2023. J.P. Morgan and Leerink Partners are acting as joint book-running managers, further demonstrating the offering's market confidence.
Read more →WVE▲ +9.2%on this news· ran to -34% by day 3shared move
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
Wave Life Sciences has initiated dosing in the RestorAATion clinical trial program for WVE-006, its RNA editing candidate intended to treat alpha-1 antitrypsin deficiency (AATD). This milestone follows a $20 million payment received from GSK, with potential future milestone payments reaching up to $505 million. WVE-006 aims to restore healthy alpha-1 antitrypsin protein levels while reducing dysfunctional proteins linked to the disease. Expected proof-of-mechanism data will be available in 2024, marking a significant step forward for both the company and patients with limited treatment options.
Read more →WVE▼ -9.5%on this news
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update Initiated RestorAATion clinical program for WVE-006, industry s first-ever RNA editing clinical candidate, following approval o
Wave Life Sciences reported its third quarter 2023 financial results, highlighting the initiation of its RestorAATion clinical program for WVE-006, which is the first RNA editing clinical candidate. The company anticipates proof-of-mechanism data for WVE-006 in 2024 and plans to deliver dystrophin data from the FORWARD-53 trial in the same year. They also noted a significant increase in financial health, reporting a net income of $7.3 million, attributed to successful collaborations. Additionally, Wave announced progress on its new GalNAc-siRNA program for metabolic disorders, focusing on obesity.
Read more →WVE▲ +6%on this news
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
Wave Life Sciences Ltd. will host a live webcast and conference call on November 9, 2023, to review its third quarter 2023 financial results and provide business updates. The event will begin at 8:30 a.m. ET and includes a Q&A session for analysts. An archived version of the webcast will also be made available after the live event. The company's ongoing commitment is to deliver impactful RNA medicines for various diseases.
Read more →WVE▲ +8.7%on this newsshared move
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disor
Wave Life Sciences recently held its annual R&D Day, outlining its strategy to become a leader in RNA medicines. The company presented preclinical proof-of-concept data for its novel program targeting INHBE, aimed at treating metabolic disorders like obesity. Additionally, Wave's first RNA editing clinical candidate, WVE-006, is set for dosing in the upcoming RestorAATion clinical trial. The company plans to advance multiple RNA editing targets and expects to select five new clinical candidates by the end of 2025.
Read more →WVEWave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
Wave Life Sciences Ltd. will present at the Chardan 7th Annual Genetic Medicines Conference on October 2, 2023, in New York City. CEO Paul Bolno will join an ADAR Editing Panel and an analyst-led fireside chat. The event will be available for live streaming and replays on their website. This participation emphasizes the company's focus on innovative RNA medicines aimed at treating genetic diseases.
Read more →WVEWave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that its CEO, Paul Bolno, will take part in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation is scheduled for September 11, 2023, and will be accessible via the company's Investor Relations page. This event highlights the company's ongoing commitment to developing innovative RNA medicines for genetically defined diseases.
Read more →WVEWave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
Wave Life Sciences has announced the submission of its first clinical trial application for WVE-006, marking the beginning of clinical development for the first-ever RNA editing therapeutic candidate aimed at treating alpha-1 antitrypsin deficiency (AATD). The company plans to initiate dosing in healthy volunteers in Q4 2023 and expects to deliver restoration data by 2024. Additionally, WVE-006 is a part of a collaboration with GSK, which includes potential milestone payments for the company. Wave emphasizes the pioneering nature of RNA editing technology and its anticipated therapeutic benefits for patients with AATD.
Read more →WVE▲ +15.8%on this news
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the in
Wave Life Sciences has reported its financial results for the second quarter of 2023, highlighting significant advancements in its clinical pipeline. The company is preparing for the submission of clinical trial applications for its first RNA editing candidate, WVE-006, aimed at treating alpha-1 antitrypsin deficiency (AATD). Furthermore, Wave is on track to initiate a Phase 2 study for its DMD candidate, WVE-N531, later this year. Despite a disappointing discontinuation of WVE-004, the company announced a strong financial position and ongoing collaboration with GSK, which has positively impacted its revenue.
Read more →WVEWave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
Wave Life Sciences Ltd. is scheduled to host a live webcast and conference call on August 3, 2023, at 8:30 a.m. ET to discuss its second quarter 2023 financial results. The event will include business updates and a Q&A session for analysts. An archived version of the webcast will be available on the company's website following the live event. Wave Life Sciences focuses on developing RNA medicines for various genetically defined diseases using its proprietary PRISM platform.
Read more →WVEWave Life Sciences Joins the Russell 2000 and Russell 3000 Indexes
Wave Life Sciences Ltd. has announced its inclusion in the Russell 2000 and Russell 3000 indexes, effective June 26, 2023. This addition marks a significant milestone for the company, reflecting its growth and enhancing its visibility among institutional investors. Being part of these indexes could lead to increased investment opportunities and recognition in the market.
Read more →WVEWave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Potent and durable target engagement observed acros
Wave Life Sciences announced topline results from its Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as a treatment for C9orf72-associated ALS and frontotemporal dementia. Although the study showed potent and durable target engagement with significant reductions in poly(GP) biomarkers, no clinical benefit compared to placebo was observed. As a result, Wave has decided to discontinue the development of WVE-004. The company aims to use the findings to help inform future research and is advancing other programs related to Huntington's disease and muscular dystrophy.
Read more →WVE▼ -7.9%on this news
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
Wave Life Sciences will present its advanced RNA editing capabilities and multimodal platform at the ASGCT Annual Meeting. Notable data includes WVE-006, a candidate showing promise in reducing markers of liver disease for alpha-1 antitrypsin deficiency. The presentations will also discuss best-in-class exon skipping results in Duchenne muscular dystrophy using WVE-N531. The company aims to revolutionize treatment for devastating diseases through its novel RNA medicines.
Read more →WVEWave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Ra
Wave Life Sciences reported its financial results for Q1 2023, highlighting a collaboration with GSK that granted $170 million in upfront cash. The company is set to submit its first RNA editing candidate, WVE-006, for clinical trials this year and anticipates a Phase 2 study for WVE-N531 in Duchenne muscular dystrophy patients. Despite a net loss of $27.4 million, Wave is well-capitalized with $207.6 million in cash, sufficient to fund operations into 2025, and plans to showcase further developments in an upcoming investor event.
Read more →WVEWave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
Wave Life Sciences Ltd. will host a live webcast and conference call on May 3, 2023, at 8:30 a.m. ET to discuss its first quarter financial results and provide business updates. Interested participants can access the conference via a dedicated audio link and are encouraged to engage during the Q&A segment. Following the live event, an archived version of the webcast will be made available on the company's website. Wave Life Sciences is focused on developing genetic medicines to treat genetically defined diseases.
Read more →WVEWave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Wave Life Sciences announced the publication of preclinical data demonstrating the effectiveness of its small interfering RNA (siRNA) designs in the journal Nucleic Acids Research. The data showed that Wave's siRNA maintains approximately 80% silencing of HSD17B13 transcripts for up to three months in transgenic mice, outperforming comparator siRNA formats. The study highlights improvements in potency and Ago2 loading due to Wave's novel chemistry modifications, further enhancing its RNAi capabilities. The company aims to leverage these advancements for potential collaborations, including ongoing work with GSK.
Read more →WVE▲ +8.5%on this news
Wave Life Sciences to Present at the Guggenheim Genomic Medicines and Rare Disease Days
Wave Life Sciences Ltd. will present at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on April 3, 2023. CEO Paul Bolno will take part in an analyst-led fireside chat, sharing insights about the company’s work in genetic medicines. A live webcast and a replay of the presentation will be available on their corporate website, showcasing their commitment to developing treatments for genetically defined diseases.
Read more →WVE▼ -10.4%on this news
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Achieved clinical validation of PRISM platform in 2022 demonstrated ability to potently and durably engage RNA t
Wave Life Sciences reported its financial results for Q4 and full year 2022, highlighting the clinical validation of its PRISM platform and progress in RNA editing. The company is advancing its first-in-class candidate WVE-006 for alpha-1 antitrypsin deficiency and is set to initiate Part B of the WVE-N531 trial for Duchenne muscular dystrophy. A strategic collaboration with GSK is expected to bolster its pipeline and potential revenue. However, Wave reported an increase in net losses compared to the previous year, attributed mainly to higher clinical program expenditures.
Read more →WVEWave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Wave Life Sciences Ltd. will host a live webcast to discuss its fourth quarter and full year 2022 financial results on March 22, 2023. This conference call aims to provide a business update for stakeholders and analysts. Investors can access this event through the company's investor relations website. An archived version of the webcast will also be available following the event.
Read more →WVEWave Life Sciences to Present at the 2023 Virtual SVB Securities Global Biopharma Conference
Wave Life Sciences Ltd. is set to participate in the upcoming SVB Securities Global Biopharma Conference, where CEO Paul Bolno will host a fireside chat. This event, scheduled for February 16, 2023, highlights the company’s dedication to genetic medicines as it strives to provide treatments for severe diseases. Attendees can access the presentation via a live webcast and find archived replays on the company's investor relations website.
Read more →WVEWave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy 53% mean exon skipping and 1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multido
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy 53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology of WVE-N531 compa
Read more →WVE▲ +32.7%on this news· ran to +67% by day 1
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets Wave receives upfront payment of $170 million in cash and equity, als
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets Wave receives upfront payment of $170 million in cash and equity, also eligible to receive milestone payments and royalties C
Read more →WVE▲ +5.8%on this news· ran to -19% by day 3shared move
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well
Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive update in third quarter from SELECT-HD trial in HD; single doses of WVE-003 appeared generally safe and well-tolerated and suggested allele-selective reduction of mHTT
Read more →WVE▼ -14.9%on this news· ran to -27% by day 3shared move
Wave Life Sciences to Present at the Stifel 2022 Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences to Webcast Conference Call of Third Quarter 2022 Financial Results on November 10, 2022
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences to Highlight Advancements from PRISM Platform at Upcoming Scientific Congresses
Six presentations and posters between OTS and ESGCT meetings will highlight Wave’s oligonucleotide chemistry advancements as well as RNA editing and RNAi capabilities First presentation in a scientific congress of preclinical data supporting WVE-006 as a potential best-in-class
Read more →WVEWave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event WVE-006 is the most advanced candidate
Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT prot
Read more →WVEWave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVE▲ +8.3%on this news
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington s Disease Single doses of WVE-003 appear general
Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington s Disease Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) p
Read more →WVEWave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
CAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast
Read more →WVE▲ +16.9%on this news· ran to +45% by day 3
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA
Wave Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in first-in-class RNA editing candidate and most advanced program currently in develo
Read more →WVE▼ -5.6%on this news· ran to -17% by day 3
Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022
CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering
Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering CAMBRIDGE, Mass., June 14, 2022 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating disease
Read more →WVEWave Life Sciences to Present at the 2022 Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVE▼ -12.2%on this news
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Delivered first clinical data demonstrating target engagement and translation of PN chemistry s impact in clinic; Adapting ongo
Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update Delivered first clinical data demonstrating target engagement and translation of PN chemistry s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose l
Read more →WVE▼ -9.8%on this newsshared move
Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast
Read more →WVE▲ +5.8%on this news· ran to +16% by day 3
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional variants and poly(GP) dipeptide repeat proteins in mice for at least six months while maintaining C9orf72 protein levels Recently reported clinical dat
Read more →WVEWave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVE▲ +14.3%on this news
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004 Reductions in poly(GP), a key disease biomarker indica
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004 Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment grou
Read more →WVEWave Life Sciences to Present at Stifel 2022 CNS Days
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences to Highlight RNA Base Editing Modality and Alpha-1 Antitrypsin Deficiency Program at Upcoming Scientific and Industry Meetings
Presentation at OPT 2022 to highlight AATD program, including reduction of liver aggregates with repeat AIMer dosing out to 19 weeks Multiple presentations and panel discussions at 3rd Annual RNA Editing Summit to highlight Wave’s leadership in therapeutic RNA base editing CAMB
Read more →WVE▼ -9.9%on this news
Wave Life Sciences Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme
Published data demonstrate potent, durable, and specific editing and potential for therapeutic applications in liver using a subcutaneous GalNAc-conjugated oligonucleotide approach Wave’s foundational AIMer technology avoids limitations of other base editing approaches reliant o
Read more →WVEWave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in
Wave Life Sciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Clinical data from multiple novel, PN-modified stereopure oligonucleotides for ALS/FTD, DMD, and HD expected in 2022 GalNAc-AIMers restore therapeutically relevant levels of AA
Read more →WVE▼ -7.8%on this news· ran to -18% by day 3
Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Announces Two Papers in the Journal Nucleic Acids Research Describing How PN Backbone Chemistry Modifications Enhance the Pharmacological Effects of Oligonucleotides
Wave paper on PN chemistry for silencing in the CNS, and the implications for oligonucleotides more broadly, designated as a Breakthrough Article by Nucleic Acids Research Publications highlight the profound impact of PN chemistry on potency, distribution, and durability of effe
Read more →WVEWave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepati
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update Strengthened balance sheet with approximately $52 million; focusing additional investment in RNA editing programs led by hepatic Optimized AIMers for AATD program demonstrate potent, hi
Read more →WVEWave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVE▼ -10.1%on this news
Wave Life Sciences and Takeda Amend CNS Collaboration Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize
Wave Life Sciences and Takeda Amend CNS Collaboration Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR to co-develop and co-commercialize late-stage CNS programs, including clinical programs WVE-004 and WVE-003, rema
Read more →WVE▼ -9.4%on this news
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne Muscular Dystrophy
Trial is expected to enroll 15 boys with DMD amenable to exon 53 skipping First systemically administered therapeutic candidate with PN backbone chemistry modifications to be assessed in the clinic Preclinical in vivo data with PN backbone chemistry modified-exon skipping compo
Read more →WVE▼ -12.3%on this newsshared move
Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multiple Tissues and Provides Update on AATD Program During Analyst and Investor Research Webcast
Durable ADAR editing in vivo in preclinical models, including in CNS tissues with editing out to at least four months Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mas
Read more →WVE▼ -12.3%on this newsshared move
Analyst & Investor Research Webcast
Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, b
Read more →WVEWave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease
Only clinical-stage candidate for Huntington’s disease designed to selectively lower mutant HTT and spare wild-type HTT Adaptive trial design to enable faster optimization of dosing and decision-making on next steps for WVE-003; data to be generated through 2022 WVE-003 preclin
Read more →WVEWave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021
CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RN
Read more →WVEWave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RN
Read more →WVEWave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVE▲ +8.6%on this news
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD first oligonucleotide using PN backbone chemistry mod
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clini
Read more →WVE▼ -6.2%on this news
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021
CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVE▲ +6.4%on this news
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
First clinical dosing of a compound using PN backbone chemistry modifications Enrolling participants with C9-ALS, C9-FTD or mixed phenotype FOCUS-C9 is adaptive to enable rapid optimization of WVE-004 dosing Clinical data to enable decision-making on next steps for WVE-004 pro
Read more →WVEWave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
Read more →WVEWave Life Sciences to Present at Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs ex
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Clinical trials underway with next-generation candidates incorporating PN chemistry Clinical data from PN chemistry programs expected in 2022 In vivo ADAR editing data for AATD program
Read more →WVEWave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast
Read more →WVEWave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD Trials mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trial
Wave Life Sciences Provides Update on Phase 1b/2a PRECISION-HD mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new
Read more →WVEWave Life Sciences to Present at the Third Annual Stifel CNS Day
CAMBRIDGE, Mass., March 19, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021
Wave Life Sciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021 Data from ongoing PRECISION-HD and OLE clinical trials for Hunti
Read more →WVEWave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
Read more →WVEWave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed
Read more →WVEWave Life Sciences to Present at the 29th Annual Credit Suisse Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021 Dosing in
Wave Life Sciences Reports Third Quarter 2020 Financial Results and Provides Business Update Results from all cohorts of PRECISION-HD1 and PRECISION-HD2 clinical trials and initial OLE data on track for 1Q 2021 Dosing in three new clinical trials with novel compounds incorpora
Read more →WVEWave Life Sciences to Webcast Conference Call of Third Quarter 2020 Financial Results on November 9, 2020
CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences Announces Proposed Public Offering of Ordinary Shares
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares CAMBRIDGE, Mass., September 22, 2020 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating disea
Read more →WVEWave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it will highlight its ADAR (adeno
Read more →WVEWave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020
Read more →WVEWave Life Sciences to Highlight PRISM Platform Advancements and Preclinical Neurology Pipeline During Analyst and Investor Research Webcast
Neurology pipeline discussion will include new preclinical data for C9orf72 program for ALS and FTD Platform advancements to be shared include new in vivo RNA editing data Live webcast scheduled for Tuesday, August 25th at 10:00 a.m. ET CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE N
Read more →WVEWave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
Read more →WVEWave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has appointed Kenneth Rhodes, Ph
Read more →WVEWave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update Data from both PRECISION-HD clinical trials expected in 2H 2020 Advancing clinical neurology pipeline SNP3 and C9orf72 programs
Wave Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update Data from both PRECISION-HD clinical trials expected in 2H 2020 Advancing clinical neurology pipeline SNP3 and C9orf72 programs on track to initiate clinical development in 2H 2020 Fir
Read more →WVEWave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020
CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webca
Read more →WVEWave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Innovative pipeline of stereopure oligonucleotides focused on CNS diseases 32 mg data from both PRECISION-HD cli
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Innovative pipeline of stereopure oligonucleotides focused on CNS diseases 32 mg data from both PRECISION-HD clinical trials on track for 2H 2020 Two additional CNS programs SN
Read more →WVEWave Life Sciences to Present at the Cowen and Company 40th Annual Healthcare Conference
CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference
CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will present preclinical data f
Read more →WVEWave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
CAMBRIDGE, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcas
Read more →WVEWave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington s Disease WVE-120102 demonstrates statistically significant reduction in disease-causi
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington s Disease WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in No difference in total HTT prote
Read more →WVEWave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy No change from baseline in dystrophin observed in Phase 1 open-label extension study Wave to host investor conference
Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy No change from baseline in dystrophin observed in Phase 1 open-label extension study Wave to host investor conference call at 8:00 a.m. ET today CAMBRIDGE, Mass., December 16
Read more →WVEWave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open
Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019 Topline data f
Read more →WVEWelcome Paul Bolno, MD, MBA President and CEO Wave Life Sciences Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this do
Analyst and Investor Research Day OCTOBER 7, 2019 BOSTON, MASSACHUSETTS Exhibit 99.1 Welcome Paul Bolno, MD, MBA President and CEO Wave Life Sciences Forward-looking statements This document contains forward-looking statements. All statements other than statements of histori
Read more →WVEWave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen
Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping Clinical dystrophin data from interim analysis of ongoing OLE study on track for 4Q 2019 DYSTANCE 51 global Phase 2/3 trial is underway CAM
Read more →WVEWave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019
CAMBRIDGE, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will host a Research Day for analys
Read more →WVEWave Life Sciences Expands Board of Directors with Three New Appointments New independent directors bring deep expertise in drug development, commercial operations and government affairs
Wave Life Sciences Expands Board of Directors with Three New Appointments New independent directors bring deep expertise in drug development, commercial operations and government affairs CAMBRIDGE, Mass., September 5, 2019 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage
Read more →WVEWave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Appoints Mark Baldry as Chief Commercial Officer
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the appointment of Mark Baldry as Chief
Read more →WVEWave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, pl
Wave Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update Interim efficacy data from ongoing suvodirsen open-label extension study on track for 4Q 2019 Phase 2/3 DYSTANCE 51 global, placebo-controlled study of suvodirsen initiated First topl
Read more →WVEWave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally CAMBRIDGE, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-sta
Read more →WVEWave Life Sciences to Present at Parent Project Muscular Dystrophy 2019 Annual Conference
CAMBRIDGE, Mass., June 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Michael Panzara, MD, MPH, Chief Me
Read more →WVEWave Life Sciences to Present at the Jefferies 2019 Healthcare Conference
CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and
Read more →WVEWave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update
Wave Life Sciences Reports First Quarter 2019 Financial Results and Provides Business Update CAMBRIDGE, Mass., May 10, 2019 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling dev
Read more →WVEWave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase
Wave Life Sciences Announces Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in
Read more →WVEWave Life Sciences to Host Investor Conference Call to Discuss Suvodirsen DMD Clinical Data Being Presented at MDA Clinical and Scientific Conference
Suvodirsen Phase 1 Safety and Tolerability Results Accepted for Oral Presentation Investor Conference Call and Webcast Scheduled for Tuesday, April 16 CAMBRIDGE, Mass., April 12, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines
Read more →WVEWave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs
Read more →WVEWave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference
CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that four poster presentations highlig
Read more →WVEWave Life Sciences to Present at the Cowen 39th Annual Health Care Conference
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President an
Read more →WVEWave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update Outlines plans for building a fully integrated genetic medicines company
Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Outlines plans for building a fully integrated genetic medicines company CAMBRIDGE, Mass., March 1, 2019 Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicine
Read more →WVEWave Life Sciences Prices $150 Million Public Offering of Ordinary Shares
Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares CAMBRIDGE, Mass., January 24, 2019 Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious, genetically-defined diseas
Read more →WVEWave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program
Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21st Century Cures Act initiative CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering t
Read more →WVEWave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD) WVE-210201 safety and tolerability profile supports Phase 2/3 clinical trial initiation in boys with DMD amenable
Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD) WVE-210201 safety and tolerability profile supports Phase 2/3 clinical trial initiation in boys with DMD amenable to exon 51 skipping Delivery of interim efficacy data fr
Read more →WVEWave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass., November 9, 2018 Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically
Read more →WVEWave Life Sciences to Present at the Jefferies 2018 London Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chi
Read more →WVEWave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290 Initial development candidate expected in H2 2019 CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on deliver
Read more →WVEAcknowledgements & Disclosures All Wave Life Sciences employees Prof. Gregory Verdine, co-founder & Director Wave Life Sciences Prof. Takeshi Wada, co-founder Wave Life Sciences Prof. Matthew Wood, Department of Physiolo
Stereochemical Control of Antisense Oligonucleotides Enhances Target Efficacy Chandra Vargeese, PhD SVP, Drug Discovery Wave Life Sciences October 3, 2018 Exhibit 99.1 Acknowledgements & Disclosures All Wave Life Sciences employees Prof. Gregory Verdine, co-founder & Director
Read more →WVEWave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings
Wave Life Sciences to Present New Data on Its DMD Exon 53 Skipping Program and Discovery Platform at Upcoming Meetings
Read more →WVEWave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that the U.S. Food and Drug Administration
Read more →WVEWave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update
Wave Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass, August 9, 2018 Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-d
Read more →WVEWave Life Sciences Initiates Clinical Development of WVE-210201 in Patients with Duchenne Muscular Dystrophy
Wave Life Sciences Initiates Clinical Development of WVE-210201 in Patients with Duchenne Muscular Dystrophy
Read more →WVEWave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201
Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping Patients currently enrolling in global Phase 1 clinical trial CAMBRIDGE, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a
Read more →WVEWave Life Sciences to Present at Parent Project Muscular Dystrophy Annual Conference
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chie
Read more →WVEWave Life Sciences to Present at the Jefferies 2018 Healthcare Conference
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, M.D., MBA, President and Chi
Read more →WVEWave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update
Wave Life Sciences Reports First Quarter 2018 Financial Results and Provides Business Update CAMBRIDGE, Mass., May 9, 2018 Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defi
Read more →WVEWave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer
With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on deliverin
Read more →WVEWave Life Sciences to Present Data on ALS and FTD Programs and on Huntington's Disease at the 2018 American Academy of Neurology Annual Meeting
CAMBRIDGE, Mass., April 17, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, will present key data on its amyotrophic lateral sclerosis
Read more →WVEWave Life Sciences and Deep Genomics Form Collaboration to Discover Novel Therapies for Genetic Neuromuscular Disorders
CAMBRIDGE, Mass. and TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., a biotechnology company
Read more →WVEForward looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future
Wave Life Sciences Corporate Presentation April 2, 2018 Exhibit 99.1 Forward looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or as
Read more →WVEWave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Ne
Wave Life Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Neurology pipeline growing; candidate in spinocerebellar ataxia typ
Read more →WVEWave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in eq
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research supp
Read more →WVEWave Life Sciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Paul Bolno, MD, MBA, President and Chie
Read more →WVEPreclinical Data for WVE-3972-01 Supporting ALS and FTD Programs Robert Brown, Jr., DPhil, MD Chair and Professor of Neurology at the University of Massachusetts Medical School 28th International Symposium on ALS/MND
Preclinical Data for WVE-3972-01 Supporting ALS and FTD Programs Robert Brown, Jr., DPhil, MD Chair and Professor of Neurology at the University of Massachusetts Medical School 28th International Symposium on ALS/MND December 10, 2017 Jr., DPhil, MD is Chair and Professor of
Read more →WVEWave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update
Wave Life Sciences Reports Third Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass., November 9, 2017 Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically
Read more →WVEWave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update
Wave Life Sciences Reports Second Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass., August 9, 2017 Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-
Read more →WVEWave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
Wave Life Sciences Initiates Two Phase 1b/2a Clinical Trials: PRECISION-HD1 and PRECISION-HD2 in Patients with Huntington’s Disease
Read more →WVEWAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update
WAVE Life Sciences Reports First Quarter 2017 Financial Results and Provides Business Update CAMBRIDGE, Mass., May 10, 2017 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today
Read more →WVEWAVE Life Sciences Prices Public Offering of 4,166,667 Ordinary Shares CAMBRIDGE, Mass. (BUSINESS WIRE)
WAVE Life Sciences Prices Public Offering of 4,166,667 Ordinary Shares CAMBRIDGE, Mass. (BUSINESS WIRE) April 12, 2017 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced t
Read more →WVEWAVE Life Sciences Announces Proposed Public Offering of Ordinary Shares CAMBRIDGE, Mass. (BUSINESS WIRE)
WAVE Life Sciences Announces Proposed Public Offering of Ordinary Shares CAMBRIDGE, Mass. (BUSINESS WIRE) April 11, 2017 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, announced
Read more →WVEWAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update On track to take first three lead programs into the clinic in 2017 Clinical trials expected to commence in Hunti
WAVE Life Sciences Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Business Update On track to take first three lead programs into the clinic in 2017 Clinical trials expected to commence in Huntington s disease mid-2017, Duchenne Muscular Dystrophy sec
Read more →WVEForward Looking Statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future
Corporate Presentation January 6, 2017 Forward Looking Statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operati
Read more →WVEWAVE Life Sciences Appoints Christian Henry to its Board of Directors
WAVE Life Sciences Appoints Christian Henry to its Board of Directors CAMBRIDGE, Mass. November 10, 2016 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the appoi
Read more →WVEWAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update
WAVE Life Sciences Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass., November 9, 2016 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, to
Read more →WVEWAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer
WAVE Life Sciences Appoints Keith Regnante as Chief Financial Officer CAMBRIDGE, Mass. August 17, 2016 WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients impacted by rare diseases, today announ
Read more →WVEWAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update On track to file two INDs for lead programs in Huntington s disease in 2016 and IND for lead program in Duchenne muscular dyst
WAVE Life Sciences Reports Second Quarter 2016 Financial Results and Provides Business Update On track to file two INDs for lead programs in Huntington s disease in 2016 and IND for lead program in Duchenne muscular dystrophy in Current financial position supports continued pip
Read more →WVEWAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
WAVE Life Sciences Receives Orphan Drug Designation from FDA for its Lead Candidate Designed to Treat Huntington’s Disease
Read more →WVEWAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update On track to deliver six clinical programs by 2018, including two IND filings in 2016 Entered collaboration with Pfizer to devel
WAVE Life Sciences Reports First Quarter 2016 Financial Results and Provides Business Update On track to deliver six clinical programs by 2018, including two IND filings in 2016 Entered collaboration with Pfizer to develop genetically targeted therapies for the treatment of met
Read more →WVEWAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases Collaboration will combine WAVE s proprietary antisense and RNAi capabilities with Gal
WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically Targeted Therapies for the Treatment of Metabolic Diseases Collaboration will combine WAVE s proprietary antisense and RNAi capabilities with GalNAc and Pfizer s hepatic targeting technology for potenti
Read more →WVEWAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update On track to file two INDs for lead programs in Huntington s disease in 2016; Advancing over 20 discovery program
WAVE Life Sciences Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update On track to file two INDs for lead programs in Huntington s disease in 2016; Advancing over 20 discovery programs for genetically defined rare and other serious diseases
Read more →WVEWAVE Life Sciences (Nasdaq: WVE) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Feb. 16, 2016 (GLOBE NEWSWIRE) -- WAVE Life Sciences (Nasdaq:WVE), a genetic medicine company focused on advancing potential best-in-class stereopure nucleic acid therapies, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Paul Bolno, Presid
Read more →WVEWAVE Life Sciences Announces Pricing of Initial Public Offering
WAVE Life Sciences Announces Pricing of Initial Public Offering
Read more →Competitive Position
How WVE ranks across every disease it competes inCompetitive Position is a premium feature
See how WVE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial